A portrait of the sialyl glycan receptor specificity of the H10 influenza virus hemagglutinin—a picture of an avian virus on the verge of becoming a pandemic?

Elena K. Schneider, Jian Li, Tony Velkov

Research output: Contribution to journalReview ArticleResearchpeer-review

1 Citation (Scopus)

Abstract

Pandemic influenza is a constant global threat to human health. In particular, the pandemic potential of novel avian influenza viruses such as the H10N7 and H10N8 avian strains, which recently managed to cross the species barrier from birds to humans, are always of great concern as we are unlikely to have any prior immunity. Human and avian isolates of H10 influenza display the ability to rapidly adapt to replication in mammalian hosts. Fortunately, so far there is no evidence of efficient human-to-human transmission of any avian influenza virus. This review examines all of the available clinical and biological data for H10 influenza viruses with an emphasis on hemagglutinin as it is a major viral antigen that determines host range and immunity. The available glycan binding data on the influenza H10 hemagglutinin are discussed in a structure-recognition perspective. Importantly, this review raises the question of whether the emerging novel avian H10 influenza viruses truly represents a threat to global health that warrants close monitoring.

Original languageEnglish
Article number51
Number of pages15
JournalVaccines
Volume5
Issue number4
DOIs
Publication statusPublished - 13 Dec 2017

Keywords

  • Glycan specificity
  • H10
  • Hemagglutinin
  • Influenza

Cite this

@article{0f908ca542724a0381b95e384d28baa2,
title = "A portrait of the sialyl glycan receptor specificity of the H10 influenza virus hemagglutinin—a picture of an avian virus on the verge of becoming a pandemic?",
abstract = "Pandemic influenza is a constant global threat to human health. In particular, the pandemic potential of novel avian influenza viruses such as the H10N7 and H10N8 avian strains, which recently managed to cross the species barrier from birds to humans, are always of great concern as we are unlikely to have any prior immunity. Human and avian isolates of H10 influenza display the ability to rapidly adapt to replication in mammalian hosts. Fortunately, so far there is no evidence of efficient human-to-human transmission of any avian influenza virus. This review examines all of the available clinical and biological data for H10 influenza viruses with an emphasis on hemagglutinin as it is a major viral antigen that determines host range and immunity. The available glycan binding data on the influenza H10 hemagglutinin are discussed in a structure-recognition perspective. Importantly, this review raises the question of whether the emerging novel avian H10 influenza viruses truly represents a threat to global health that warrants close monitoring.",
keywords = "Glycan specificity, H10, Hemagglutinin, Influenza",
author = "Schneider, {Elena K.} and Jian Li and Tony Velkov",
year = "2017",
month = "12",
day = "13",
doi = "10.3390/vaccines5040051",
language = "English",
volume = "5",
journal = "Vaccines",
issn = "2076-393X",
publisher = "MDPI",
number = "4",

}

A portrait of the sialyl glycan receptor specificity of the H10 influenza virus hemagglutinin—a picture of an avian virus on the verge of becoming a pandemic? / Schneider, Elena K.; Li, Jian; Velkov, Tony.

In: Vaccines, Vol. 5, No. 4, 51, 13.12.2017.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - A portrait of the sialyl glycan receptor specificity of the H10 influenza virus hemagglutinin—a picture of an avian virus on the verge of becoming a pandemic?

AU - Schneider, Elena K.

AU - Li, Jian

AU - Velkov, Tony

PY - 2017/12/13

Y1 - 2017/12/13

N2 - Pandemic influenza is a constant global threat to human health. In particular, the pandemic potential of novel avian influenza viruses such as the H10N7 and H10N8 avian strains, which recently managed to cross the species barrier from birds to humans, are always of great concern as we are unlikely to have any prior immunity. Human and avian isolates of H10 influenza display the ability to rapidly adapt to replication in mammalian hosts. Fortunately, so far there is no evidence of efficient human-to-human transmission of any avian influenza virus. This review examines all of the available clinical and biological data for H10 influenza viruses with an emphasis on hemagglutinin as it is a major viral antigen that determines host range and immunity. The available glycan binding data on the influenza H10 hemagglutinin are discussed in a structure-recognition perspective. Importantly, this review raises the question of whether the emerging novel avian H10 influenza viruses truly represents a threat to global health that warrants close monitoring.

AB - Pandemic influenza is a constant global threat to human health. In particular, the pandemic potential of novel avian influenza viruses such as the H10N7 and H10N8 avian strains, which recently managed to cross the species barrier from birds to humans, are always of great concern as we are unlikely to have any prior immunity. Human and avian isolates of H10 influenza display the ability to rapidly adapt to replication in mammalian hosts. Fortunately, so far there is no evidence of efficient human-to-human transmission of any avian influenza virus. This review examines all of the available clinical and biological data for H10 influenza viruses with an emphasis on hemagglutinin as it is a major viral antigen that determines host range and immunity. The available glycan binding data on the influenza H10 hemagglutinin are discussed in a structure-recognition perspective. Importantly, this review raises the question of whether the emerging novel avian H10 influenza viruses truly represents a threat to global health that warrants close monitoring.

KW - Glycan specificity

KW - H10

KW - Hemagglutinin

KW - Influenza

UR - http://www.scopus.com/inward/record.url?scp=85041912362&partnerID=8YFLogxK

U2 - 10.3390/vaccines5040051

DO - 10.3390/vaccines5040051

M3 - Review Article

VL - 5

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 4

M1 - 51

ER -